Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (24)

2024

  1. Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis

    Kidney International, Vol. 105, Núm. 1, pp. 177-188

2023

  1. Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

    Kidney360, Vol. 4, Núm. 5, pp. 659-672

  2. Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation

    Nephrology Dialysis Transplantation, Vol. 38, Núm. 1, pp. 222-235

2022

  1. Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

    Clinical Kidney Journal, Vol. 15, Núm. 9, pp. 1737-1746

  2. Factor H-Related Protein 1 Drives Disease Susceptibility and Prognosis in C3 Glomerulopathy

    Journal of the American Society of Nephrology : JASN, Vol. 33, Núm. 6, pp. 1137-1153

  3. Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 7, pp. 1270-1280

2021

  1. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

    Kidney International, Vol. 99, Núm. 4, pp. 986-998

  2. Validation of a Histologic Scoring Index for C3 Glomerulopathy

    American Journal of Kidney Diseases, Vol. 77, Núm. 5, pp. 684-695.e1

2020

  1. Mycophenolate mofetil in c3 glomerulopathy and pathogenic drivers of the disease

    Clinical Journal of the American Society of Nephrology, Vol. 15, Núm. 9, pp. 1287-1298

  2. Risk factors for non-diabetic renal disease in diabetic patients

    Clinical Kidney Journal, Vol. 13, Núm. 3, pp. 380-388

2019

  1. IgA nephropathy in elderly patients

    Clinical Journal of the American Society of Nephrology, Vol. 14, Núm. 8, pp. 1183-1192

2018

  1. Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis

    Clinical Journal of the American Society of Nephrology, Vol. 13, Núm. 12, pp. 1851-1858

  2. Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients

    Kidney International Reports, Vol. 3, Núm. 1, pp. 122-132

2016

  1. Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis

    Clinical Kidney Journal, Vol. 9, Núm. 3, pp. 381-386

2015

  1. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis

    Kidney International, Vol. 88, Núm. 5, pp. 1153-1160

2012

  1. Diagnosis and treatment of Lupus nephritis: Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish society of internal medicine (SEMI) and the Spanish society of nephrology (S.E.N.)

    Nefrologia, Vol. 32, Núm. SUPPL. 1, pp. 1-45

  2. Diagnosis and treatment of lupus nephritis

    Revista Clinica Espanola

  3. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria

    Journal of the American Society of Nephrology, Vol. 23, Núm. 10, pp. 1753-1760

  4. Nefritis lúpica: En busca de un futuro mejor

    Nefrologia

2009

  1. A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function

    Clinical Transplantation, Vol. 23, Núm. 1, pp. 23-32